Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Cancer Therapy: Clinical

A Phase I Study of In vitro Expanded Natural Killer T Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer

Shinichiro Motohashi, Aki Ishikawa, Eiichi Ishikawa, Mizuto Otsuji, Toshihiko Iizasa, Hideki Hanaoka, Naomi Shimizu, Shigetoshi Horiguchi, Yoshitaka Okamoto, Shin-ichiro Fujii, Masaru Taniguchi, Takehiko Fujisawa and Toshinori Nakayama
Shinichiro Motohashi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aki Ishikawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eiichi Ishikawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mizuto Otsuji
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshihiko Iizasa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hideki Hanaoka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naomi Shimizu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shigetoshi Horiguchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshitaka Okamoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shin-ichiro Fujii
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masaru Taniguchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takehiko Fujisawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshinori Nakayama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-06-0114 Published October 2006
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: Human Vα24 natural killer T (Vα24 NKT) cells bearing an invariant Vα24JαQ antigen receptor are activated by a glicolipid ligand α-galactosylceramide (αGalCer; KRN7000) in a CD1d-dependent manner. The human Vα24 NKT cells activated with αGalCer and interleukin-2 have been shown to produce large amounts of cytokines, such as IFN-γ, and also exerting a potent killing activity against various tumor cell lines. We did a phase I study with autologous activated Vα24 NKT cell therapy.

Experimental Design: Patients with advanced or recurrent non–small cell lung cancer received i.v. injections of activated Vα24 NKT cells (level 1: 1 × 107/m2 and level 2: 5 × 107/m2) to test the safety, feasibility, and clinical response of this therapeutic strategy. Immunomonitoring was also done in all cases.

Results: Six patients were enrolled in this study. No severe adverse events were observed during this study in any patients. After the first and second injection of activated Vα24 NKT cells, an increased number of peripheral blood Vα24 NKT cells was observed in two of three cases receiving a level 2 dose of activated Vα24 NKT cells. The number of IFN-γ-producing cells in peripheral blood mononuclear cells increased after the administration of activated Vα24 NKT cells in all three cases receiving the level 2 dose. No patient was found to meet the criteria for either a partial or a complete response.

Conclusions: The clinical trial with activated Vα24 NKT cell administration was well tolerated and carried out safely with minor adverse events even in patients with advanced diseases.

  • NKT cell
  • clinical trial
  • immunotherapy

Footnotes

  • Grant support: Ministry of Education, Culture, Sports, Science and Technology (Japan) grants-in-aid for Scientific Research in Priority Areas #17016010 and #17047007, Scientific Research B #17390139, and Scientific Research C #18590466; grant-in-aid for Young Scientists #17790317; and Special Coordination Funds for Promoting Science and Technology; Ministry of Health, Labor and Welfare (Japan); Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (Japan); Cancer Translational Research Project; The Japan Health Science Foundation; Kanae Foundation; and Uehara Memorial Foundation and Mochida Foundation.

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

    • Accepted May 11, 2006.
    • Received January 17, 2006.
    • Revision received May 10, 2006.
View Full Text
PreviousNext
Back to top
Clinical Cancer Research: 12 (20)
October 2006
Volume 12, Issue 20
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Phase I Study of In vitro Expanded Natural Killer T Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A Phase I Study of In vitro Expanded Natural Killer T Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer
Shinichiro Motohashi, Aki Ishikawa, Eiichi Ishikawa, Mizuto Otsuji, Toshihiko Iizasa, Hideki Hanaoka, Naomi Shimizu, Shigetoshi Horiguchi, Yoshitaka Okamoto, Shin-ichiro Fujii, Masaru Taniguchi, Takehiko Fujisawa and Toshinori Nakayama
Clin Cancer Res October 15 2006 (12) (20) 6079-6086; DOI: 10.1158/1078-0432.CCR-06-0114

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Phase I Study of In vitro Expanded Natural Killer T Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer
Shinichiro Motohashi, Aki Ishikawa, Eiichi Ishikawa, Mizuto Otsuji, Toshihiko Iizasa, Hideki Hanaoka, Naomi Shimizu, Shigetoshi Horiguchi, Yoshitaka Okamoto, Shin-ichiro Fujii, Masaru Taniguchi, Takehiko Fujisawa and Toshinori Nakayama
Clin Cancer Res October 15 2006 (12) (20) 6079-6086; DOI: 10.1158/1078-0432.CCR-06-0114
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Biomarker Analysis from the BERIL-1 Study
  • Radiation and TGFβ Blockade in Metastatic Breast Cancer
  • Tamoxifen Metabolism and Efficacy in Breast Cancer
Show more Cancer Therapy: Clinical
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement